[go: up one dir, main page]

MX2010006650A - Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica. - Google Patents

Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.

Info

Publication number
MX2010006650A
MX2010006650A MX2010006650A MX2010006650A MX2010006650A MX 2010006650 A MX2010006650 A MX 2010006650A MX 2010006650 A MX2010006650 A MX 2010006650A MX 2010006650 A MX2010006650 A MX 2010006650A MX 2010006650 A MX2010006650 A MX 2010006650A
Authority
MX
Mexico
Prior art keywords
treatment
materials
methods
vascular proliferation
ocular vascular
Prior art date
Application number
MX2010006650A
Other languages
English (en)
Inventor
Maria B Grant
Josef Neu
Joshua Anthony
Kristin Morris
Eduard Poels
Deborah Schade
Hugh Tucker
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2010006650A publication Critical patent/MX2010006650A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención en cuestión se proporciona para la administración de ácido docosahexaenoico en la prevención de proliferación patológica de vasos sanguíneos; las composiciones de la invención en cuestión son particularmente útiles ya que son estables, biodisponibles y pueden ser formuladas en una solución acuosa.
MX2010006650A 2007-12-17 2008-12-17 Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica. MX2010006650A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1418007P 2007-12-17 2007-12-17
PCT/US2008/087125 WO2009079544A1 (en) 2007-12-17 2008-12-17 Materials and methods for treatment of pathological ocular vascular proliferation

Publications (1)

Publication Number Publication Date
MX2010006650A true MX2010006650A (es) 2010-09-28

Family

ID=40411080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006650A MX2010006650A (es) 2007-12-17 2008-12-17 Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.

Country Status (8)

Country Link
US (1) US20090192226A1 (es)
EP (1) EP2219639A1 (es)
CN (1) CN101939000A (es)
BR (1) BRPI0820802A2 (es)
CA (1) CA2709579A1 (es)
MX (1) MX2010006650A (es)
RU (1) RU2010129825A (es)
WO (1) WO2009079544A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012107695A (ru) * 2009-07-31 2013-09-10 Нестек С.А. Питательная композиция для вскармливаемых грудью детей или домашних животных с пробиотиками и подобранными питательными веществами
EP2289527B1 (en) * 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
CN103442725A (zh) * 2011-01-25 2013-12-11 雀巢产品技术援助有限公司 治疗、减轻或预防动物的视觉系统衰退的方法和组合物
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
CN103948581B (zh) * 2014-02-26 2018-05-08 青岛大学医学院附属医院 左卡尼汀联合l-精氨酸在制备治疗糖尿病视网膜病变神经损伤药物中的应用
DE102015101273A1 (de) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
CN109010264A (zh) * 2018-08-18 2018-12-18 河北科技大学 一种ω-3脂肪酸或ω-3脂肪酸酯制剂及其新用途
US20220226443A1 (en) * 2019-05-28 2022-07-21 Elgan Pharma Ltd Compositions and methods for treating retinopathy
JP2024542280A (ja) * 2021-12-01 2024-11-13 セインダ ファーマシューティカル グアンジョウ コーポレイション アラニル－グルタミンおよびアラニル－グルタミンを含む眼科用組成物の新規な使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU209973B (en) * 1988-03-09 1995-01-30 Biorex Kutato Fejlesztoe Kft Process for production of antiviral and immunstimular pharmaceutical composition
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
WO2003017787A1 (en) * 2001-08-23 2003-03-06 University Of Florida Dipeptides for prevention of muscle breakdown and microbial infection
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
WO2005030243A1 (en) * 2003-09-26 2005-04-07 Bristol Myers Squibb Company Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
WO2005110375A1 (en) * 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
RU2400102C2 (ru) * 2005-08-26 2010-09-27 Нестек С.А. Композиция для лечения, замедления или предотвращения у животного слабоумия, старения мозга, когнитивного нарушения, инсульта или болезни альцгеймера и ее применение (варианты)
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
WO2008143642A2 (en) * 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids

Also Published As

Publication number Publication date
RU2010129825A (ru) 2012-01-27
US20090192226A1 (en) 2009-07-30
CN101939000A (zh) 2011-01-05
WO2009079544A1 (en) 2009-06-25
CA2709579A1 (en) 2009-06-25
BRPI0820802A2 (pt) 2015-06-16
EP2219639A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
EP3147285A3 (en) Purinone compounds as kinase inhibitors
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
EP2444491A3 (en) Hyperglycosylated human coagulation factor IX
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
WO2010068866A3 (en) Therapeutic particles suitable for parenteral administration and methods of making and using same
MX374806B (es) Metodo, fabricacion y uso de productos medicos que liberan sustancia activa para mantener vasos sanguineos abiertos
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
WO2009085969A3 (en) Compositions and methods to promote implantation and engrafment of stem cells
NZ596236A (en) Inhibitors of human immunodeficiency virus replication
MY153039A (en) Thioacetate compounds,compositions and methods of use
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
MY162146A (en) Pharmaceutical composition
WO2008008770A3 (en) 6, 9-disubstituted purine derivatives and their use for treating skin
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2009120919A3 (en) Fenofibrate dosage forms
HK1216717A1 (zh) 用於治療葡萄糖轉運體1缺乏症的三庚酸甘油酯
MX342947B (es) Tratamiento de diabetes tipo 2.
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
MX2014004710A (es) Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
WO2010129347A3 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal